Bilal Abid, MD, of the University of Texas Health Science Center at Houston, discusses how to approach sequencing pirtobrutinib after chimeric antigen receptor (CAR) T-cell therapy for the management of hematologic malignancies at the Twelfth Annual Meeting of the Society of Hematologic Oncology.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.